LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 43

Search options

  1. Article ; Online: Artificial intelligence and prediction of cardiometabolic disease: Systematic review of model performance and potential benefits in indigenous populations.

    Jeong, Keunwoo / Mallard, Alistair R / Coombe, Leanne / Ward, James

    Artificial intelligence in medicine

    2023  Volume 139, Page(s) 102534

    Abstract: Background: Indigenous peoples often have higher rates of morbidity and mortality associated with cardiometabolic disease (CMD) than non-Indigenous people and this may be even more so in urban areas. The use of electronic health records and expansion of ...

    Abstract Background: Indigenous peoples often have higher rates of morbidity and mortality associated with cardiometabolic disease (CMD) than non-Indigenous people and this may be even more so in urban areas. The use of electronic health records and expansion of computing power has led to mainstream use of artificial intelligence (AI) to predict the onset of disease in primary health care (PHC) settings. However, it is unknown if AI and in particular machine learning is used for risk prediction of CMD in Indigenous peoples.
    Methods: We searched peer-reviewed literature using terms associated with AI machine learning, PHC, CMD, and Indigenous peoples.
    Results: We identified 13 suitable studies for inclusion in this review. Median total number of participants was 19,270 (range 911-2,994,837). The most common algorithms used in machine learning in this setting were support vector machine, random forest, and decision tree learning. Twelve studies used the area under the receiver operating characteristic curve (AUC) to measure performance. Two studies reported an AUC of >0.9. Six studies had an AUC score between 0.9 and 0.8, 4 studies had an AUC score between 0.8 and 0.7. 1 study reported an AUC score between 0.7 and 0.6. Risk of bias was observed in 10 (77 %) studies.
    Conclusion: AI machine learning and risk prediction models show moderate to excellent discriminatory ability over traditional statistical models in predicting CMD. This technology could help address the needs of urban Indigenous peoples by predicting CMD early and more rapidly than conventional methods.
    MeSH term(s) Humans ; Artificial Intelligence ; Machine Learning ; Algorithms ; Indigenous Peoples ; Cardiovascular Diseases/diagnosis
    Language English
    Publishing date 2023-03-28
    Publishing country Netherlands
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 645179-2
    ISSN 1873-2860 ; 0933-3657
    ISSN (online) 1873-2860
    ISSN 0933-3657
    DOI 10.1016/j.artmed.2023.102534
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study.

    Rao, Amanda / Ebelt, Phillippa / Mallard, Alistair / Briskey, David

    Sleep science and practice

    2021  Volume 5, Issue 1, Page(s) 12

    Abstract: Background: Sleep is essential for wellbeing, yet sleep disturbance is a common problem linked to a wide range of health conditions. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide proposed to promote better sleep via potential interaction ...

    Abstract Background: Sleep is essential for wellbeing, yet sleep disturbance is a common problem linked to a wide range of health conditions. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide proposed to promote better sleep via potential interaction with the endocannabinoid system.
    Methods: This double-blind, randomised study on 103 adults compared the efficacy and tolerability of 8 weeks of daily supplemented PEA formulation (350 mg Levagen + ®) to a placebo. Sleep quality and quantity were measured using wrist actigraphy, a sleep diary and questionnaires.
    Results: At week 8, PEA supplementation reduced sleep onset latency, time to feel completely awake and improved cognition on waking. After 8 weeks, both groups improved their sleep quality and quantity scores similarly. There was no difference between groups at baseline or week 8 for sleep quantity or quality as measured from actigraphy or sleep diaries.
    Conclusion: These findings support PEA as a potential sleeping aid capable of reducing sleep onset time and improving cognition on waking.
    Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12618001339246. Registered 9
    Language English
    Publishing date 2021-09-10
    Publishing country England
    Document type Journal Article
    ISSN 2398-2683
    ISSN (online) 2398-2683
    DOI 10.1186/s41606-021-00065-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study

    Amanda Rao / Phillippa Ebelt / Alistair Mallard / David Briskey

    Sleep Science and Practice, Vol 5, Iss 1, Pp 1-

    2021  Volume 8

    Abstract: Abstract Background Sleep is essential for wellbeing, yet sleep disturbance is a common problem linked to a wide range of health conditions. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide proposed to promote better sleep via potential ... ...

    Abstract Abstract Background Sleep is essential for wellbeing, yet sleep disturbance is a common problem linked to a wide range of health conditions. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide proposed to promote better sleep via potential interaction with the endocannabinoid system. Methods This double-blind, randomised study on 103 adults compared the efficacy and tolerability of 8 weeks of daily supplemented PEA formulation (350 mg Levagen + ®) to a placebo. Sleep quality and quantity were measured using wrist actigraphy, a sleep diary and questionnaires. Results At week 8, PEA supplementation reduced sleep onset latency, time to feel completely awake and improved cognition on waking. After 8 weeks, both groups improved their sleep quality and quantity scores similarly. There was no difference between groups at baseline or week 8 for sleep quantity or quality as measured from actigraphy or sleep diaries. Conclusion These findings support PEA as a potential sleeping aid capable of reducing sleep onset time and improving cognition on waking. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12618001339246 . Registered 9th August 2018.
    Keywords Palmitoylethanolamide ; Levagen ; Sleep ; Sleep onset ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: An urgent call to collect data related to COVID-19 and Indigenous populations globally.

    Mallard, Alistair / Pesantes, Maria Amalia / Zavaleta-Cortijo, Carol / Ward, James

    BMJ global health

    2021  Volume 6, Issue 3

    MeSH term(s) COVID-19/epidemiology ; COVID-19/ethnology ; COVID-19/prevention & control ; COVID-19/therapy ; Data Collection/methods ; Data Collection/standards ; Epidemiologic Methods ; Humans ; Indigenous Peoples/statistics & numerical data ; Public Health ; SARS-CoV-2 ; Vulnerable Populations
    Language English
    Publishing date 2021-02-28
    Publishing country England
    Document type Journal Article
    ISSN 2059-7908
    ISSN 2059-7908
    DOI 10.1136/bmjgh-2020-004655
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: An urgent call to collect data related to COVID-19 and Indigenous populations globally

    Maria Amalia Pesantes / James Ward / Carol Zavaleta-Cortijo / Alistair Mallard

    BMJ Global Health, Vol 6, Iss

    2021  Volume 3

    Keywords Medicine (General) ; R5-920 ; Infectious and parasitic diseases ; RC109-216
    Language English
    Publishing date 2021-03-01T00:00:00Z
    Publisher BMJ Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and exercise.

    Mallard, Alistair R / Spathis, Jemima G / Coombes, Jeff S

    Free radical biology & medicine

    2020  Volume 160, Page(s) 471–479

    Abstract: Chronic metabolic health diseases are increasing worldwide placing strain on healthcare systems and importantly, impacting individuals' quality of life. It is well established that many chronic diseases are associated with inflammation and oxidative ... ...

    Abstract Chronic metabolic health diseases are increasing worldwide placing strain on healthcare systems and importantly, impacting individuals' quality of life. It is well established that many chronic diseases are associated with inflammation and oxidative stress. Exercise is a known strategy to manage and treat inflammation in animals and humans. Understanding the mechanisms which cause acute and chronic changes to systems via various exercise protocols may provide insights into how we can better clinically manage patients with inflammatory and oxidative stress associated diseases. Nrf2 is a basic leucine transcription factor which regulates the expression of antioxidant proteins to protect against damage caused by electrophilic or oxidative stress. The aim of this narrative review is to provide an overview of the literature which has investigated the relationship between acute and chronic exercise training and Nrf2 protein, mRNA and Nrf2-ARE binding activity. This narrative review presents analysis of twenty-nine articles presenting studies using animals and humans. Findings from animal models suggest that exercise increases all molecular aspects of the Nrf2-ARE pathway in all tissues studied. It was noted that there seems to be an age-related decline in Nrf2 protein upregulation with exercise training. In humans, however, there is a lack of evidence to support this claim.
    MeSH term(s) Animals ; Antioxidants ; Exercise ; Humans ; NF-E2-Related Factor 2/genetics ; NF-E2-Related Factor 2/metabolism ; Oxidative Stress ; Quality of Life
    Chemical Substances Antioxidants ; NF-E2-Related Factor 2
    Language English
    Publishing date 2020-08-29
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 807032-5
    ISSN 1873-4596 ; 0891-5849
    ISSN (online) 1873-4596
    ISSN 0891-5849
    DOI 10.1016/j.freeradbiomed.2020.08.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The effect of an orally-dosed Caralluma Fimbriata extract on appetite control and body composition in overweight adults.

    Rao, Amanda / Briskey, David / Dos Reis, Carla / Mallard, Alistair R

    Scientific reports

    2021  Volume 11, Issue 1, Page(s) 6791

    Abstract: To examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. A double-blind, randomised, placebo controlled trial to examine the effect of a Caralluma Fimbriata extract (CFE) on ... ...

    Abstract To examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. A double-blind, randomised, placebo controlled trial to examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. Eighty-three men and women aged between 20 and 50 years of age completed 16 weeks of daily supplementation with either CFE or placebo. Plasma cardiometabolic (lipid profile, glucose, insulin) and satiety (ghrelin, leptin, neuropeptideY) biomarkers, body composition, diet history and gastrointenstinal function were assessed at baseline, weeks 4, 8, 12 and 16. Subjects in the CFE and placebo groups were well matched and predominatly female 93% and 87.5%, with a mean age of 40.9 ± 6.7 and 39.5 ± 7.5 years and body mass index (BMI) of 30.0 ± 3.1 and 30.2 ± 2.9 kg/m
    MeSH term(s) Administration, Oral ; Adult ; Apocynaceae/chemistry ; Apocynaceae/metabolism ; Appetite Depressants/chemistry ; Appetite Depressants/pharmacology ; Appetite Depressants/therapeutic use ; Appetite Regulation/drug effects ; Biomarkers/blood ; Body Mass Index ; Double-Blind Method ; Energy Intake/drug effects ; Humans ; Leptin/blood ; Middle Aged ; Overweight/diet therapy ; Overweight/pathology ; Placebo Effect ; Plant Extracts/chemistry ; Plant Extracts/pharmacology ; Plant Extracts/therapeutic use ; Waist Circumference/drug effects ; Young Adult
    Chemical Substances Appetite Depressants ; Biomarkers ; Leptin ; Plant Extracts
    Language English
    Publishing date 2021-03-24
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-021-86108-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The effect of an orally-dosed Caralluma Fimbriata extract on appetite control and body composition in overweight adults

    Amanda Rao / David Briskey / Carla dos Reis / Alistair R. Mallard

    Scientific Reports, Vol 11, Iss 1, Pp 1-

    2021  Volume 9

    Abstract: Abstract To examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. A double-blind, randomised, placebo controlled trial to examine the effect of a Caralluma Fimbriata extract (CFE) on ...

    Abstract Abstract To examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. A double-blind, randomised, placebo controlled trial to examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. Eighty-three men and women aged between 20 and 50 years of age completed 16 weeks of daily supplementation with either CFE or placebo. Plasma cardiometabolic (lipid profile, glucose, insulin) and satiety (ghrelin, leptin, neuropeptideY) biomarkers, body composition, diet history and gastrointenstinal function were assessed at baseline, weeks 4, 8, 12 and 16. Subjects in the CFE and placebo groups were well matched and predominatly female 93% and 87.5%, with a mean age of 40.9 ± 6.7 and 39.5 ± 7.5 years and body mass index (BMI) of 30.0 ± 3.1 and 30.2 ± 2.9 kg/m2 respectively. There was a significant difference in plasma leptin concentration change between groups at week 16 (p = 0.04), with the placebo group increasing concentration (2.27 ± 4.80 ng/mL) while the CFE group (0.05 ± 4.69 ng/mL) remained the same. At week 16, the CFE group had significantly reduced their calorie intake from baseline compared to the placebo group (245 cal vs 15.8 cal respectively p < 0.01). The CFE group also had a significant reduction in waist circumference of 2.7 cm compared to an increase of 0.3 cm in the placebo group (p = 0.02). A weight increase from baseline was seen in the placebo group that was not observed in the CFE group (1.33 kg weight gain vs 0.37 kg weight loss respectively; p = 0.03). The placebo group also had a significant increase in fat mass, android fat mass, BMI and leptin compared to the CFE group (p = 0.04, 0.02, < 0.01 respectively). CFE was effective at maintaining bodyweight during a non-calorie controlled diet compared to a placebo. The mechanism responsible for this action is requiring further research and could be due to an increase in satiety receptor sensitivity.
    Keywords Medicine ; R ; Science ; Q
    Subject code 796
    Language English
    Publishing date 2021-03-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article: Curcumin Improves Delayed Onset Muscle Soreness and Postexercise Lactate Accumulation

    Mallard, Alistair R. / Briskey, David / Richards, BExSSc, Andrew / Rao, Amanda

    Journal of dietary supplements. 2021 Aug. 23, v. 18, no. 5

    2021  

    Abstract: The efficacy of curcumin supplementation is traditionally limited due to its poor bioavailability. Despite this, curcumin has previously been shown to improve biomarkers of muscle damage. The addition of a novel drug delivery system that improves ... ...

    Abstract The efficacy of curcumin supplementation is traditionally limited due to its poor bioavailability. Despite this, curcumin has previously been shown to improve biomarkers of muscle damage. The addition of a novel drug delivery system that improves bioavailability could improve exercise recovery. The purpose of this randomized double-blind placebo-controlled study was to assess the effect of curcumin (combined with LipiSperse) when consumed as a drink on exercise recovery in recreationally trained healthy males aged 18–35 yrs. The study included 28 young healthy males with strength training experience. The participants undertook lower limb resistance exercise to exhaustion. Fourteen participants received curcumin dispersed in water pre and postexercise and 14 received a matched placebo drink. Pain (visual analogue scale), thigh circumference (TC), lactate, creatine kinase, lactate dehydrogenase, high sensitivity C-reactive protein, myoglobin, interleukin-6, interleukin-10, and tumor necrosis factor-alpha were assessed pre, postexercise and 1, 2, 3, 24, 48, and 72 h postexercise. There was less appearance of postexercise capillary lactate in the curcumin group compared to placebo (7.4 vs 8.8 mmol/L). The placebo group rated overall muscle pain as higher compared to the curcumin group at 48- and 72-h postexercise. TC was reduced in the curcumin group compared to the placebo group at 24- and 48-h postexercise. The results suggest curcumin may facilitate a quicker return to exercise training and/or allow a higher training intensity than a placebo by reducing postexercise pain, modulating inflammatory pathways and reducing lactate accumulation in an exercising population.
    Keywords C-reactive protein ; bioavailability ; biomarkers ; creatine kinase ; curcumin ; drug delivery systems ; interleukin-10 ; interleukin-6 ; lactate dehydrogenase ; lactic acid ; muscles ; myoglobin ; pain ; placebos ; strength training ; tumor necrosis factor-alpha
    Language English
    Dates of publication 2021-0823
    Size p. 531-542.
    Publishing place Taylor & Francis
    Document type Article
    ZDB-ID 2460305-3
    ISSN 1939-022X ; 1939-0211
    ISSN (online) 1939-022X
    ISSN 1939-0211
    DOI 10.1080/19390211.2020.1796885
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  10. Article ; Online: The Effect of Orally Dosed Levagen+™ (palmitoylethanolamide) on Exercise Recovery in Healthy Males-A Double-Blind, Randomized, Placebo-Controlled Study.

    Mallard, Alistair / Briskey, David / Richards, Andrew / Mills, Dean / Rao, Amanda

    Nutrients

    2020  Volume 12, Issue 3

    Abstract: The aim of this study was to evaluate the effect of palmitoylethanolamide (PEA), a cannabimimetic compound and lipid messenger, on recovery from muscle damaging exercise. Twenty-eight healthy young male participants attended the laboratory four times on ... ...

    Abstract The aim of this study was to evaluate the effect of palmitoylethanolamide (PEA), a cannabimimetic compound and lipid messenger, on recovery from muscle damaging exercise. Twenty-eight healthy young male participants attended the laboratory four times on subsequent days. In the first visit, baseline characteristics were recorded before participants were randomized to consume either liquid PEA (167.5 mg Levagen+ with 832.5 mg maltodextrin) or a matched placebo (1 g maltodextrin) drink. Leg press exercise consisted of four sets at 80% of one repetition maximum followed by a performance set. Muscle soreness, thigh circumference, blood lactate concentration, biomarkers of muscle damage and inflammation, and transcription factor pathways were measured pre- and immediately post-exercise and again at 1, 2, 3, 24, 48, and 72 h post-exercise. The leg press exercise increased (
    MeSH term(s) Adult ; Amides/administration & dosage ; Biomarkers/blood ; Biomarkers/metabolism ; Cannabinoid Receptor Agonists/administration & dosage ; Double-Blind Method ; Ethanolamines/administration & dosage ; Exercise/physiology ; Healthy Volunteers ; Humans ; Lactic Acid/blood ; Lactic Acid/metabolism ; Male ; Muscle, Skeletal/drug effects ; Muscle, Skeletal/metabolism ; Muscle, Skeletal/physiopathology ; Myalgia/blood ; Myalgia/drug therapy ; Myalgia/etiology ; Myoglobin/blood ; Myoglobin/metabolism ; Palmitic Acids/administration & dosage ; Treatment Outcome ; Tumor Necrosis Factor-alpha/blood ; Tumor Necrosis Factor-alpha/metabolism ; Young Adult
    Chemical Substances Amides ; Biomarkers ; Cannabinoid Receptor Agonists ; Ethanolamines ; Myoglobin ; Palmitic Acids ; TNF protein, human ; Tumor Necrosis Factor-alpha ; Lactic Acid (33X04XA5AT) ; palmidrol (6R8T1UDM3V)
    Language English
    Publishing date 2020-02-25
    Publishing country Switzerland
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu12030596
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top